From April 28 to May 3, 2018, Seinda participated in the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), held in Honolulu, Hawaii, USA. During the event, Seinda officially introduced its latest tear biomarker-based point-of-care (POC) diagnostic solutions for ocular surface diseases, namely the LTA-POC, IgE-POC, and MMP9-POC.

● The LTA-POC supports the diagnosis and stratification of dry eye disease (DED), assisting in the selection of appropriate treatment pathways based on individual patient profiles.

● The IgE-POC enables the diagnosis of IgE-mediated allergic conjunctivitis and facilitates direct, targeted treatment selection.

● The MMP9-POC is designed for the detection of inflammation-induced ocular surface damage, providing clinicians with timely and actionable diagnostic insights.

Seinda’s cutting-edge tear biomarker POCT technology received strong interest from conference attendees. A wide range of ophthalmology professionals visited the Seinda booth to learn more about the products and experience live demonstrations. The solutions’ rapid, accurate, and user-friendly in vitro diagnostic capabilities were particularly well-received and praised for their potential to enhance clinical decision-making and patient care.

Seinda remains committed to advancing ophthalmic diagnostics through innovation and continues to collaborate with clinicians and researchers worldwide to deliver impactful solutions for eye health.